Phase 1 study of combination therapy with L-697,661 and zidovudine

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 12, Issue 4, 1996, Pages 363-370

  Schooley, Robert T ^a,h   Campbell, Thomas B ^a   Kuritzkes, Daniel R ^a   Blaschke, Terrence ^e   Stein, Daniel S ^f   Rosandich, Mary E ^a   Phair, John ^c   Pottage, John C ^c   Messari, Ferdinand ^g   Collier, Ann ^d   Kahn, James ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e STANFORD UNIVERSITY   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Combination therapy; Human immunodeficiency virus 1; L 697,661; Pharmacokinetic interactions; Zidovudine

Indexed keywords

3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; PYRIDONE DERIVATIVE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG SENSITIVITY; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR INTERACTION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RETROVIRUS; VIRUS ISOLATION; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; UNIDENTIFIED RETROVIRUS;

EID: 9544254970     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199608010-00006     Document Type: Article

References (34)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine in the treament of patients with AIDS and AIDS related complex. N Engl J Med 1987;317:185-91.
2. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine in the treatment of subjects with mildly symptomatic human immunodeficiency virus infection. Ann Intern Med 1990;112:727-37.
3. Volberding PA, Lagakos SW, Koch MA, et al., and the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500-CD4 positive cells per cubic millimeter. N Engl J Med 1990;323:1009-14.
4. Kahn JO, Logakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327:581-7.
5. Merigan TC, Skowron G, Bozette SA, et al., and the ddC Study Group of the AIDS Clinical Trials Group. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. Ann Intern Med 1989;110:189-94.
6. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science 1989;243:1731-4.
7. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high level resistance to zidovudine (AZT). Science 1989;246:1155-8.
8. St Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557-9.
9. Zhengxian G, Gao Q, Xuguang L, Parniak MA, Wainberg MA. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′ dideoxyinosine and 2′,3′ didexycytidine. J Virol 1992;66:7128-35.
10. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus, type-1 in the blood of infected persons. N Engl J Med 1989;321:1621-5.
11. Pauwels R, Andries K, Desmyter J, et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990;343:470-4.
12. Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990;250:1411-3.
13. Goldman ME, Nunberg JH, O'Brien JA, et al. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci USA 1991;88:6863-7.
14. Romero DL, Busso M, Tan CK, et al. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency type 1 replication. Proc Natl Acad Sci USA 1991;88:8806-10.
15. Goldman ME, O'Brien JA, Ruffing TL, et al. L-696,229 specifically inhibits HIV-1 reverse transcriptase and posesses antiviral activity in virtro. Antimicrob Agents Chemother 1992;36:1019-23.
16. Richman DD, Rosenthal AS, Skoog M, et al. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 1991;35:305-8.
17. Nunberg JH, Schleif WA, Boots EJ, et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol 1991;65:4887-92.
18. Richman DD, Shih C-K, Lowy I, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991;88:11241-5.
19. Vessell ES. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther 1979; 26:275-86.
20. Granich GG, Eveland MR, Krogstad DJ. Fluorescence polarization immunoassay for zidovudine. Antimicrob Agents Chemother 1989;33:1275-9.
21. Weber A, Opheim K, Smith AL. Simplified high performance liquid chromatographic quantitation of antipyrine. J Chromatogr Sci 1984;22(6):2239-40.
22. AIDS clinical trials group (ACTG) virology manual. United States Government Printing Office, 1993.
23. Nishanian P, Huskins KR, Stehn S, et al. A simple method for improved assay demonstrates that HIV p24 antigen is present as immune complexes in most sera from HIV-infected individuals. J Infect Dis 1990;162:21-28.
24. Japour AJ, Mayers DL, Johnson VA, et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus Type 1 isolates. Antimicrob Agents Chemother 1993;37:1095-101.
25. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzymatic inhibitors. Adv Enzyme Regul 1984;22:27-55.
26. Larder BA, Boucher CAB. Polymerase chain reaction detection of human immunodeficiency virus drug resistance mutations. In: Pershing DH et al., eds. Diagnostic molecular biology, principles and applications. Washington, D.C.: American Society for Microbiology, 1993;527-33.
27. Straus NA, Zagursky RJ. In vitro production of large single-stranded templates for DNA sequencing. Biotechniques 1991;10:376-84.
28. Saag MS, Emini EA, Laskin OL, et al, and the L-697,661 Working Group. The nonnucleoside HIV-1 reverse transcriptase inhibitor L-697,661: clinical activity and rapid selection for virus variants with reduced susceptibility. N Engl J Med 1993;329:1065-72.
29. Cheeseman SH, and the ACTG 164/168 Study Team. Nevirapine (NVP) alone and in combination with zidovudine. Eighth International Conference on AIDS, Amsterdam, The Netherlands, July 19-24, 1992.
30. Staszewski S, Massari FE, Kober A, et al. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor. J Infect Dis 1995;171:1159-65.
31. Demeter LM, Resnick L, Tarpley WG, et al. Prolonged sensitivity of HIV-1 isolates to atevirdine (ATV) in a phase 1 clinical trial of ATV and zidovudine (ZDV). (ACTG 199) PO-A26-0643. Ninth International Conference on AIDS, Berlin, June 6-11, 1993.
32. Larder BA, Kemp SD, Harrigan R. Potential mechanism for sustained antiretroviral efficacy of AZT/3TC combination therapy. Science 1995;269:696-9.
33. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-6.
34. Wei X, Ghosh S, Taylor M, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373: 117-22.